Peptide Advisor

Written By: Steve Fong | Medically Reviewed by: One Day MD Editorial Team TL;DR: Losing weight fast on Ozempic is great, but it often leaves behind "Ozempic Body" (sagging skin and a hollow face). Doctors are now using stem cells, exosomes, and nanofat to rebuild the body from the inside out. Here is the science behind why weight loss needs a regenerative upgrade. Abstract The rapid global adoption of glucagon-like peptide-1 (GLP-1) receptor agonists—such as semaglutide and tirzepatide—has revolutionized obesity management. However, accelerated adipose tissue depletion frequently induces secondary aesthetic and structural sequelae, colloquially termed "Ozempic Body." This condition is characterized by dermal laxity, rhytids, facial lipoatrophy, and compromised extracellular matrix (ECM) integrity. This paper evaluates the synergistic integration of regenerative medicine modalities—specifically mesenchymal stem cell (MSC) therapy, nanofat grafti...

Start GLP-1 the Right Way—Not Just the Easy Way Compare options like Ozempic, Wegovy, and Mounjaro—and learn how to maximize fat loss while avoiding muscle loss and rebound weight gain. What You’ll Get: Best GLP-1 option for your goals Expected weight loss results Cost & access options Optimization strategy (critical) REALITY CHECK Most People Start GLP-1 the Wrong Way They: Pick the wrong drug Lose muscle instead of fat Hit a plateau after a few months Regain weight after stopping 👉 This guide helps you avoid that. STEP 1 — CHOOSE YOUR GLP-1 Not All GLP-1s Are the Same 🧪 Option 1: Ozempic / Wegovy Best for: Beginners Steady weight loss Typical results: ~10–15% body weight loss Pros: Well-studied Widely available Cons: Plateau risk 🔥 Option 2: Mounjaro Best for: Faster, more aggressive fat loss Insulin resistance Typical results: ~15–20% body weight loss Pros: Stronger metabolic effects Cons: Higher cost Stronger side effects COST & ACCESS How to Get GLP-1 Option A: Teleheal...

The landscape of obesity treatment has evolved dramatically with the introduction of advanced medical therapeutics like retatrutide (RETA, LY3437943), tirzepatide (Mounjaro), and semaglutide (Ozempic) . Glucagon-like peptide-1 receptor agonists and co-agonists, originally developed to manage type 2 diabetes, have shown remarkable efficacy in promoting weight loss, making them game-changers for obesity management. However, each drug has unique mechanisms, benefits, and potential applications, including emerging roles in cancer prevention. This article compares their mechanisms, clinical efficacy, broader health benefits, safety profiles, regulatory status, and practical considerations to help patients, clinicians, and informed readers understand how they stack up in 2026. Update: Are GLP-1s the first longevity drugs ? (Nature 2025) Credit: GoodRx Health Mechanism of Action Semaglutide : Semaglutide (Ozempic and Wegovy) is a glucagon-like peptide-1 receptor agonist (GLP-1 RA). It mimics...